E
Eric Weintraub
Researcher at Centers for Disease Control and Prevention
Publications - 168
Citations - 16210
Eric Weintraub is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Vaccination & Population. The author has an hindex of 46, co-authored 142 publications receiving 13791 citations. Previous affiliations of Eric Weintraub include Marshfield Clinic.
Papers
More filters
Journal ArticleDOI
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
William W. Thompson,David K. Shay,Eric Weintraub,Lynnette Brammer,Nancy Cox,Larry J. Anderson,Keiji Fukuda +6 more
TL;DR: Mortality associated with both influenza and RSV circulation disproportionately affects elderly persons, and influenza deaths have increased substantially in the last 2 decades, in part because of aging of the population, highlighting the need for better prevention measures, including more effective vaccines and vaccination programs for elderly persons.
Journal ArticleDOI
Influenza-associated hospitalizations in the United States.
William W. Thompson,David K. Shay,Eric Weintraub,Lynnette Brammer,Carolyn B. Bridges,Nancy J. Cox,Keiji Fukuda +6 more
TL;DR: Significant numbers of influenza-associated hospitalizations in the United States occur among the elderly, and the numbers of these hospitalizations have increased substantially over the last 2 decades due in part to the aging of the population.
Journal ArticleDOI
The annual impact of seasonal influenza in the US: Measuring disease burden and costs
Noelle-Angelique M. Molinari,Ismael R. Ortega-Sanchez,Mark L. Messonnier,William W. Thompson,Pascale M. Wortley,Eric Weintraub,Carolyn B. Bridges +6 more
TL;DR: The results highlight the enormous annual burden of influenza in the US, with hospitalization costs and lost productivity from missed work days and lost lives comprise the bulk of the economic burden.
Journal ArticleDOI
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration - United States, 2020.
Jeanne M. Santoli,Megan C. Lindley,Malini B. DeSilva,Elyse O. Kharbanda,Matthew F. Daley,Lisa Galloway,Julianne Gee,Mick Glover,Ben Herring,Yoonjae Kang,Paul Lucas,M Cameron Noblit,Jeanne Tropper,Tara M. Vogt,Eric Weintraub +14 more
TL;DR: On March 13, 2020, the president of the United States declared a national emergency in response to the coronavirus disease 2019 (COVID-19) pandemic, and on March 24, CDC posted guidance emphasizing the importance of routine well child care and immunization, particularly for children aged ≤24 months, when many childhood vaccines are recommended.
Journal ArticleDOI
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Julia W. Gargano,Megan J. Wallace,Stephen C. Hadler,Gayle E Langley,John R. Su,Matthew E. Oster,Karen R. Broder,Julianne Gee,Eric Weintraub,Tom T. Shimabukuro,Heather M. Scobie,Danielle Moulia,Lauri E. Markowitz,Melinda Wharton,Veronica V. McNally,Jose R. Romero,H. Keipp Talbot,Grace M. Lee,Matthew F. Daley,Sara E. Oliver +19 more
TL;DR: In 2019, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and the Moderna COVID19 (mRNA-1273) vaccine, and the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for their use in persons aged ≥16 years and ≥18 years, respectively as mentioned in this paper.